What is self.co?
Established in 2015 by Gintautas Gylys and Tautvydas Gylys, self.co operates at the intersection of biotechnology and consumer health. The company specializes in the development of advanced molecular testing technology, specifically designed to identify and manage allergy-like symptoms. By utilizing microarray-based assays, self.co enables individuals to analyze complex biological markers from small blood samples collected either at home or within partner clinical settings. This approach democratizes access to diagnostic data, allowing for more personalized health management and proactive symptom mitigation. The firm's market position is defined by its commitment to high-precision diagnostics, positioning it as a critical infrastructure provider in the evolving digital health ecosystem.
How much funding has self.co raised?
self.co has raised a total of $3M across 2 funding rounds:
Grant
$1.6M
Unspecified
$1.4M
Grant (2025): $1.6M with participation from Innovation Agency Lithuania
Unspecified (2025): $1.4M led by Iron Wolf Capital and Coinvest Capital
Key Investors in self.co
Innovation Agency Lithuania
Inovacijų Agentūra Viskas apie verslą offers a wide range of services aimed at supporting and developing existing and emerging businesses and innovations in Lithuania.
Iron Wolf Capital
Iron Wolf Capital is a venture capital firm that invests in exceptional founders building global AI and deep tech startups in the Baltics and diaspora.
Coinvest Capital
Coinvest Capital is a venture capital fund that co-invests with business angels and other private funds in startups, focusing on enhancing the startup ecosystem in Lithuania.
What's next for self.co?
With the recent capital infusion, self.co is expected to prioritize the scaling of its laboratory operations and the expansion of its diagnostic assay portfolio. The strategic focus will likely shift toward enhancing the user experience of its at-home testing kits and strengthening partnerships with clinical networks to broaden its reach. Furthermore, the company is poised to invest in R&D to refine its molecular analysis algorithms, ensuring that its diagnostic outputs remain at the forefront of the industry. As the firm matures, it will likely explore international market entry, leveraging its established technological foundation to address the global demand for accessible, data-driven allergy and sensitivity testing solutions.
See full self.co company page
